IGM Biosciences, Inc.: restructuring charge — IGM Biosciences halts two autoimmune programs, slashes workforce 73%

IGM Biosciences, Inc.

Halted imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) trials due to insufficient B cell depletion in Phase 1b.
Workforce reduction of 73% to preserve cash; cash and investments $183.8M as of Dec 31, 2024.
Evaluating internal options and strategic alternatives to maximize shareholder value.
CEO Mary Beth Harler stated interim data did not meet high bar for success.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

IGM Biosciences, Inc. announced a restructuring affecting autoimmune disease pipeline (imvotamab and IGM-2644 programs) (approximately 73% reduction in force).

Type: restructuring
Affected area: autoimmune disease pipeline (imvotamab and IGM-2644 programs)
Headcount: approximately 73% reduction in force

Exact text from the filing

On January 9, 2025, IGM Biosciences, Inc. (the “Company”) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases (the “2025 Restructuring”). As part of the 2025 Restructuring, which was approved by the Company’s Board of Directors on January 7, 2025, the Company is taking steps, including an approximately 73% reduction in force, to preserve cash.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-25-004455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.